Tratamiento de las infecciones fúngicas en pacientes con neoplasias hematológicas

Cuenca Estrella, Manuel; Mensa, José; Gobernado, Miguel; García Rodríguez, José Ángel; Aguado, José María; Picazo, Juan; Cámara, Rafael de la; Carreras, Enric; Sanz, Miguel Ángel.
Med. clín (Ed. impr.) ; 132(13): 507-521, abr. 2009. tab
Artículo en Español | IBECS (España) | ID: ibc-60614

Documentos relacionados

  1. An evidence-based, risk-adapted algorithm for antifungal prophylaxis reduces risk for invasive mold infections in children with hematologic malignancies.
  2. Targeting immunometabolism in host-directed therapies to fungal disease.
  3. Acremonium (Sarocladium) periprosthetic joint infection: case report, literature review, and proposed antifungal regimen.
  4. [Invasive fungal infection management in patients with hematological malignancies].
  5. Advancements and challenges in antifungal therapeutic development.
  6. Population Pharmacokinetics and Pharmacodynamics of Itraconazole for Disseminated Infection Caused by Talaromyces marneffei.
  7. Drug-drug interaction: decreased posaconazole trough concentrations during concomitant flucloxacillin treatment.
  8. Post-transcriptional control of antifungal resistance in human fungal pathogens.
  9. Is There a Role for Antifungal Prophylaxis in Patients Undergoing Penile Prosthesis Surgery? A Systematic Review.
  10. [Mycosis of the maxillary sinus].